Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CellaVision AB (publ)

Healthcare US CLVSF

13.49USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

13.4913.49
LowHigh

52 Week Range

15.4523.33
LowHigh

Fundamentals

  • Previous Close 13.49
  • Market Cap378.05M
  • Volume0
  • P/E Ratio22.64
  • Dividend Yield-%
  • EBITDA221.66M
  • Revenue TTM748.45M
  • Revenue Per Share TTM31.38
  • Gross Profit TTM 517.25M
  • Diluted EPS TTM0.70

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 194.26M 176.86M 164.22M 148.43M 158.30M
Minority interest - - - - -
Net income 153.08M 140.72M 130.31M 118.33M 125.34M
Selling general administrative 90.34M 85.36M 76.03M 191.50M 165.32M
Selling and marketing expenses 129.88M 136.59M 136.62M - -
Gross profit 519.88M 487.07M 463.04M 438.32M 392.30M
Reconciled depreciation 40.05M 41.01M 39.76M 40.10M 33.44M
Ebit 204.46M 178.75M 167.48M 158.27M 162.73M
Ebitda 236.69M 219.75M 207.25M 190.87M 193.60M
Depreciation and amortization 32.23M 41.01M 39.76M - -
Non operating income net other - - - - -
Operating income 202.07M 177.68M 167.05M 158.27M 162.73M
Other operating expenses 556.89M 545.54M 510.24M - -
Interest expense 10.71M 1.89M 3.26M 2.34M 1.87M
Tax provision 41.19M 36.14M 28.77M 30.09M 32.96M
Interest income 2.90M 7.34M 0.78M 0.20M 0.06M
Net interest income -7.80900M -0.81900M 5.08M -2.14000M -1.80600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 41.19M 36.14M 33.91M 30.09M 32.96M
Total revenue 758.97M 723.22M 677.29M 639.34M 565.55M
Total operating expenses 317.80M 309.39M 295.99M 481.07M 402.82M
Cost of revenue 239.09M 236.14M 214.25M 201.02M 173.25M
Total other income expense net -7.80900M -0.81900M -2.82900M - -
Discontinued operations - - - - -
Net income from continuing ops 153.08M 140.72M 112.17M 118.33M 125.34M
Net income applicable to common shares - - - 118.33M 125.34M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1094.89M 1013.05M 928.71M 891.75M 825.21M
Intangible assets 408.20M 359.51M 99.58M 275.09M 244.07M
Earning assets - - - - -
Other current assets - 2.12M 20.11M 0.87M 0.90M
Total liab 207.31M 196.16M 212.32M 250.12M 281.93M
Total stockholder equity 887.58M 815.73M 716.39M 641.63M 543.28M
Deferred long term liab - - - 162.71M 126.28M
Other current liab 61.52M 61.55M 49.93M 7.64M 14.14M
Common stock - 3.58M 3.58M 3.58M 3.58M
Capital stock 3.58M 3.58M 3.58M 3.58M 3.58M
Retained earnings 865.07M 771.62M 684.56M 607.92M 537.28M
Other liab - - - 56.66M 51.59M
Good will 120.68M 128.14M 123.78M 124.14M 114.08M
Other assets - -0.00100M 0.00000M 168.05M 148.28M
Cash 188.22M 149.43M 121.64M 108.05M 130.29M
Cash and equivalents - - - - -
Total current liabilities 110.93M 107.95M 119.15M 133.09M 134.50M
Current deferred revenue - - 0.00000M - -
Net debt -162.56500M -122.58100M -56.94200M - -
Short term debt 13.68M 14.17M 36.04M - -
Short long term debt 13.68M 14.17M 36.04M 42.13M -
Short long term debt total 25.65M 26.85M 64.70M - -
Other stockholder equity 887.58M 10.80M 28.25M 19.33M -8.38300M
Property plant equipment - - - 110.03M 80.33M
Total current assets 441.09M 401.65M 365.59M 377.14M 364.72M
Long term investments - - - - -
Net tangible assets - - - 405.11M 311.39M
Short term investments - - - - -
Net receivables 141.07M 125.28M 97.80M 121.89M 115.50M
Long term debt 11.97M 12.68M 28.66M 60.36M -
Inventory 111.81M 124.82M 126.04M 142.57M 115.09M
Accounts payable 35.73M 32.22M 32.53M 47.86M 44.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 29.73M 17.45M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00639M 2.65M 214.26M -0.00100M -
Deferred long term asset charges - - - - -
Non current assets total 653.79M 610.24M 563.12M 514.60M 460.49M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.11M -76.00600M -87.69500M -0.58100M -0.03400M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -86.16300M -76.00600M -85.53200M -70.01400M -84.33900M
Net borrowings -1.59800M -28.96000M -31.42100M -42.70700M -30.58700M
Total cash from financing activities -74.59500M -95.08900M -97.03600M -90.41000M -48.47500M
Change to operating activities - - - 0.85M 29.03M
Net income 194.26M 176.86M 130.31M 118.33M 125.34M
Change in cash 38.79M 27.79M 13.59M -22.23300M 28.02M
Begin period cash flow 149.43M 121.64M 108.05M 130.29M 102.26M
End period cash flow 188.22M 149.43M 121.64M 108.05M 130.29M
Total cash from operating activities 200.53M 198.44M 196.44M 137.28M 159.72M
Issuance of capital stock - - - - -
Depreciation 40.05M 41.01M 39.76M 33.39M 26.69M
Other cashflows from investing activities 0.00028M 1.74M -54.70700M 0.00100M 0.00100M
Dividends paid 59.63M 53.67M 53.67M -47.70300M -17.88900M
Change to inventory 4.62M -1.71400M 12.62M -26.32300M -31.05800M
Change to account receivables - -15.79700M 7.25M -3.33000M -9.84300M
Sale purchase of stock - - - - -
Other cashflows from financing activities -13.36800M -12.46300M -11.94900M - 0.00100M
Change to netincome - - - 7.66M 12.81M
Capital expenditures 86.27M 77.75M 86.48M 23.48M 13.72M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.18600M -15.41200M 10.39M -28.80400M -11.86900M
Stock based compensation - - - - -
Other non cash items 9.45M -4.01500M 15.97M -3.13600M 6.45M
Free cash flow 114.26M 120.69M 109.96M 67.85M 75.41M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLVSF
CellaVision AB (publ)		 - -% 13.49 22.64 20.79 4.65 3.98 4.78 15.41
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

CellaVision AB (publ)

MobilvAegen 12, Lund, Sweden, 223 62

Key Executives

Name Title Year Born
Mr. Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D. Founder & Director 1965
Mr. Simon Ostergaard CEO & Pres 1971
Mr. Peter Wilson VP of Global Marketing 1967
Mr. Yve van Thorenburg Acting VP of Global Sales & Director of APAC of Global Sales 1958
Mr. Urban Strindlov VP of Global Sales 1964
Nina Wallander VP of HR 1974
Mr. Magnus Blixt Exec. Officer 1966
Mr. Julien Veyssy Managing Director of RAL Diagnostics 1983
Mr. Simon Ostergaard Ph.D. CEO & President 1971
Mr. Magnus Blixt Chief Financial Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions